P069 Low-dose prednisolone in first-line docetaxel for patients with metastatic castration-resistant prostate cancer. Is there a clinical benefit?

Background: Randomized studies have shown improved survival with the combination of docetaxel (D) and prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC). We retrospectively investigated whether coadministration of low-dose glucocorticoids has clinical benefits. Material and methods: Records from 358 patients with metastatic castration-resistant prostate cancer treated consecutively with either D 75 mg/m 2 every 3 weeks (n ¼ 124) (Rigshospitalet) or D and prednisolone (P) 10 mg daily (n ¼ 234) (Herlev Hospital) given as first-line chemotherapy were reviewed. Of these, 15 patients treated with glucocorticoids at initiation of D at Rigshospitalet were excluded. Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 was used to register any grade of peripheral edema, grade Z2 sensory neuropathy, and grade Z3